AlphAIalphai — Financial news for AI agents
gurufocus.comAUG 261 min read$ZYME

ZYME Maintains Buy Rating by Citigroup -- Price Target Raised to

Citigroup maintained a Buy rating on Zymeworks (ZYME) and raised its price target to $38.00 from $37.00. The company's GF Value™ is $20.00, suggesting a 47.1% overvaluation. Zymeworks has a GF Score™ of 60, indicating moderate performance. The stock has strong momentum but weak profitability and growth metrics.

Original reporting
gurufocus.com
Published Aug 26, 2026, 4:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 5:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$ZYME
Neutral
medium confidence
Mentioned
$ZYME
Relevance
5/10
alphai data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ZYMENeutralLow
01

Why it matters

Analyst rating lift may attract short‑term buying, but valuation concerns could cap gains.

02

Market read

The rating update provides a modest trading signal for ZYME; broader market impact is limited.

03

What to watch

Lack of insider buying and high P/S ratio suggest limited near‑term upside.

Relevance 5/10Novelty 5/10Timing: today

Background

Zymeworks is a clinical‑stage biotech with a market cap of ~$2.1 B, currently trading around $29.43.

Company-level read

Ticker impact

$ZYMENeutralMedium confidence
Context

Citigroup maintained a Buy rating and raised the price target to $38, a fresh analyst action on Zymeworks.

Expected impact

Small upside pressure if investors follow the new target; limited upside due to high valuation.

Evidence & confidence

Rating change is a primary disclosure but the magnitude is modest and the stock is already perceived as overvalued.

Market effects

Sector

Biotech sector may see slight positive bias from analyst upgrades, but broader impact limited.

Regional

North American biotech investors may adjust positions; no global ripple.

Global

Minimal; confined to Zymeworks and its immediate peers.

Counterpoint

What could challenge this read

Despite the upgraded target, the stock remains significantly overvalued; caution advised.

Key entities

  • Analyst
    Citigroup

    Maintained Buy rating and raised price target for ZYME.

Read at source← All news

Related articles

AUG 26
$ZYMEHighAI 9/10

FDA approves new indications for Ziihera

Zymeworks (ZYME) announced that its partner, Jazz Pharmaceuticals (JAZZ), received FDA approval for two Ziihera-containing regimens for treating HER2-positive gastroesophageal adenocarcinoma. This is the second FDA approval for zanidatamab in under two years, validating Zymeworks' Azymetric platform.

thepharmaletter.com2 min
AUG 26
$ZYMEHighAI 9/10

ZYME Looks 47.1% Overvalued on GF Value™

Zymeworks Inc (ZYME) shares rose 8% after FDA approval of Jazz Pharmaceuticals' Ziihera, triggering a $250M payment. ZYME's P/S ratio is 59.82x, higher than its historical median. Analysts set price targets at $55 and $40. The company's GF Score is 60, indicating moderate fundamental quality. Insiders sold $4.7M in shares over the past year.

gurufocus.com2 min
AUG 26
$ZYMEHighAI 9/10

H.C. Wainwright raises Zymeworks stock price target to $55 on FDA approval

H.C. Wainwright raised its price target on Zymeworks (ZYME) to $55 from $51, maintaining a Buy rating after FDA approval of Ziihera for HER2-positive gastroesophageal adenocarcinoma. The stock is up 85% over the past year. The approval triggers a $250 million payment from Jazz Pharmaceuticals (JAZZ). Analysts predict 188% revenue growth for FY2026. Zymeworks also announced an acquisition of Theravance Biopharma for $929 million.

investing.com2 min
AUG 25
$ZYMEHighAI 8/10

Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab

Zymeworks (ZYME) shares rose 4% in pre-market trading ahead of an FDA decision on zanidatamab, a HER2-targeting antibody, with a PDUFA target date of August 25, 2026. Approval could trigger a $250 million milestone payment and up to $190 million more in other markets. Analysts have increased price targets ahead of the decision. The company is also pursuing a $929 million acquisition of Theravance Biopharma, expected to close in late 2026.

yahoo.com2 min
AUG 25
$ZYMEHighAI 9/10

Zymeworks Inc.: U.S. FDA Approves Ziihera (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Zymeworks Inc. (ZYME) announced FDA approval for Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, for first-line HER2+ GEA treatment. This marks the second FDA approval for zanidatamab in under two years, triggering a $250 million milestone payment from Jazz Pharmaceuticals. Zymeworks could receive up to $1.3 billion in additional milestones and royalties from Jazz, and up to $144 million from BeOne Medicines. The approval is based on Phase 3 trial resul

finanznachrichten.de2 min